Clinical trials: Age Factors
Risk Behavior, Cognitive Decline
Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors associated with…
- Trial name
- NCT04616794
- Testing
- Cognitive Engagement Group, Physical Activity Group, Diet Group
- Where
- Canada
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- LuciLab
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02831751
- Testing
- 30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain)
- Where
- 15 sites in United States, Canada
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Medicago
COVID-19, SARS-COV-2 Infection
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, called BNT162b2 (2025/2026 formulation).
- Trial name
- NCT07222384
- Testing
- BNT162b2 (2025/2026 formulation)
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Vaccines
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age.
- Trial name
- NCT07730450
- Testing
- BNT162b2 Vaccine, Tdap Vaccine
- Where
- 5 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Virus Diseases, RNA Virus Infections
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine during the 2017-2018 influenza season in healthy adults 18 to 64 years of age.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03301051
- Testing
- Quadrivalent VLP Vaccine
- Where
- 73 sites in United States, Canada and 5 more
- Volunteers
- 10,160 people, healthy volunteers welcome
- Sponsor
- Medicago
Age Factor, Age-related Macular Degeneration
Flicker Fusion Thresholds Between Young and Old Subjects at Various Luminance Levels
The objective of this study is to determine which luminance levels yield maximum differences in critical flicker fusion (CFF) scores between younger and older normal subjects.
- Trial name
- NCT03079570
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Risk Behavior, Cognitive Decline
Efficacy of a Multidomain Intervention on Lifestyle Risk Factors for Dementia Prevention
Alzheimer's Disease (AD) and other Dementias have far-reaching consequences on the lives of sufferers and their loved ones, not to mention the impact on the healthcare system.
- Trial name
- NCT06748625
- Testing
- Luci Coach-Assisted Intervention
- Where
- Canada
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- LuciLab
Risk Behavior, Cognitive Decline
Multidomain Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help middle-aged to older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors…
- Trial name
- NCT05141578
- Testing
- Luci Coach Assisted Intervention
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- LuciLab
Vaping, Underage
Human Factors Validation and Usability Testing of the IKE Age-Gating System
A multi-center human factors validation study to demonstrate the function of the IKE Bluetooth system on a chip (SoC) and mobile applications ability to age-gate a device, accurately identify an individuals age, race/ethnicity…
- Trial name
- NCT06952569
- Testing
- IKE System
- Where
- 4 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- IKE Tech
Virus Diseases, RNA Virus Infections
Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02768805
- Testing
- 15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine
- Where
- 9 sites in United States, Canada
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Medicago